SCHEMBL6424422

SCHEMBL6424422

CSc1nc(O)ns1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9332434 0.72
SCHEMBL16190137 0.72
SCHEMBL4107752 0.70
SCHEMBL8115090 0.70
SCHEMBL20285553 0.65 PTGS1 (0.37)
SCHEMBL2629389 0.65
SCHEMBL25336917 0.64 ALDH1A1 (0.45)
SCHEMBL13382091 0.63 ALDH1A1 (0.41)
SCHEMBL8999546 0.60 PTGS1 (0.50)
SCHEMBL6124949 0.60

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295220-A1 C-3 AND C-17 MODIFIED TRITERPENOIDS AS HIV-1 INHIBITORS VIIV HEALTHCARE UK NO 5 LTD (GB) 2023-09-21 US disclosed
EP-3831839-B1 C-3 AND C-17 MODIFIED TRITERPENOIDS AS HIV-1 INHIBITORS VIIV HEALTHCARE UK NO 5 LTD (GB) 2023-07-26 EP disclosed
US-20210323997-A1 C-3 AND C-17 MODIFIED TRITERPENOIDS AS HIV-1 INHIBITORS VIIV Healthcare UK (No.5) Limited (GB) 2021-10-21 US disclosed
US-11084845-B2 C-3 and C-17 modified triterpenoids as HIV-1 inhibitors VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) 2021-08-10 US disclosed
EP-3831839-A2 C-3 AND C-17 MODIFIED TRITERPENOIDS AS HIV-1 INHIBITORS ViiV Healthcare UK (No.5) Limited (GB) 2021-06-09 EP disclosed
CN-109153700-B C-3 and C-17 modified triterpenoids as HIV-1 inhibitors VIIV保健英国第五有限公司 2021-03-09 CN disclosed
EP-3411381-B1 C-3 AND C-17 MODIFIED TRITERPENOIDS AS HIV-1 INHIBITORS VIIV HEALTHCARE UK NO 5 LTD (GB) 2021-01-20 EP disclosed
US-10421774-B2 C-3 and C-17 modified triterpenoids as HIV-1 inhibitors VIIV Healthcare UK (No.5) Limited (GB) 2019-09-24 US disclosed
US-20190031709-A1 C-3 AND C-17 MODIFIED TRITERPENOIDS AS HIV-1 INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2019-01-31 US disclosed
CN-109153700-A The triterpene compound that C-3 and C-17 as HIV-1 inhibitor are modified VIIV保健英国第五有限公司 2019-01-04 CN disclosed
EP-3411381-A1 C-3 AND C-17 MODIFIED TRITERPENOIDS AS HIV-1 INHIBITORS VIIV Healthcare UK (No.5) Limited (GB) 2018-12-12 EP disclosed
WO-2017134596-A1 C-3 AND C-17 MODIFIED TRITERPENOIDS AS HIV-1 INHIBITORS VIIV Healthcare UK (No.5) Limited (GB) 2017-08-10 WO disclosed
WO-2005007636-A1 1,2,4- THIADIAZOL-5-THIO COMPOUNDS AND THE DERIVATIVES THEREOF, METHODS FOR THE PRODUCTION THEREOF AND USE THEREOF AS UREASE AND NITRIFICATION INHIBITORS SKW STICKSTOFFWERKE PIESTERITZ GMBH (DE) 2005-01-27 WO disclosed
EP-1339670-A1 SUBSTITUTED CYCLOHEXANE DERIVATES AND THE USE THEREOF IN MEDICAMENTS FOR TREATING CARDIOVASCULAR DISEASES Bayer Aktiengesellschaft (DE) 2003-09-03 EP disclosed
WO-2002042257-A1 SUBSTITUTED CYCLOHEXANE DERIVATES AND THE USE THEREOF IN MEDICAMENTS FOR TREATING CARDIOVASCULAR DISEASES BAYER AKTIENGESELLSCHAFT (DE) 2002-05-30 WO disclosed
US-4069319-A 3-(DIALKYLPHOSPHORYL- OR THIOPHOSPHORYL-OXY)-1,2,4-THIADIAZOLES; INSECTICIDES, NEMATOCIDES ROUSSEL UCLAF (FR) 1978-01-17 US disclosed
US-4067720-A Certain 2-carbamoyl-1,2,4-thiadiazole-3-one herbicides ROUSSEL UCLAF (FR) 1978-01-10 US disclosed